United States - English - NLM (National Library of Medicine)

hospira, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin injection and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been prev

Canada - English - Health Canada

liquid carbonic inc. - carbon dioxide - gas - 99% - carbon dioxide 99% - miscellaneous therapeutic agents

Canada - English - Health Canada

teva canada limited - carboplatin - liquid - 10mg - carboplatin 10mg - antineoplastic agents

Canada - English - Health Canada

omega laboratories limited - carboplatin - solution - 10mg - carboplatin 10mg - antineoplastic agents

Canada - English - Health Canada

strides pharma canada inc - carboplatin - solution - 10mg - carboplatin 10mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections - carboplatin is indicated in the treatment of: advanced stage ovarian cancer of epithelial origin; small cell lung carcinoma; carcinoma of the head and neck; carcinoma of the testis; paediatric cerebral tumours; soft tissue sarcoma; neuroblastoma.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously tr

United States - English - NLM (National Library of Medicine)

eugia us llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative trea

Canada - English - Health Canada

auro pharma inc - carboplatin - solution - 10mg - carboplatin 10mg